including its vaccine candidates against COVID-19, seasonal flu, CMV, RSV, HIV and EBV; the ability to expand the Company’s portfolio of development programs; the potential to combine different vaccines into a single dose; the ability to use mRNA to enable combination therapeutics personalized ...
Dr. Salma Elfaki holds a vial of Moderna COVID-19 vaccine at a Moderna clinical trial for adolescents being conducted by Accel Research Sites with Nona Pediatric Center in Orlando.(Paul Hennessy/SOPA Images/LightRocket via Getty Images) Moderna made its request in part due to the protection t...
"We are encouraged by the primary analysis of the Phase 3 COVE study of mRNA-1273 in adults ages 18 and above and this pediatric study will help us assess the potential safety and immunogenicity of our COVID-19 vaccine candidate in this important younger age population," added Bancel. The ...
Moderna’s two-dose vaccine is one of three currently approved for use in the U.S. against COVID-19, given the green light by the Food and Drug Administration on Dec. 28. Two other shots, one by Pfizer-BioNTech and a single-dose vaccine by Johnson & Johnson, are helping to ramp up...
the potential for mRNA-1273 to provide protection from COVID-19 and severe COVID-19 disease in vaccine recipients down to 6 months of age; the safety and tolerability of mRNA-1273 in pediatric populations; and Moderna’s plans to evaluate the potent...
CHILDREN have now received their first doses of Moderna’s COVID-19 vaccine, as the company studies the safety and effectiveness of the vaccine for kids ages 6 months to less than 12 years old. In the study, researchers will give two injections 28 days apart of either the Moderna vaccine...
Because of the potential for serious adverse reactions in breastfed children, advise women not to breastfeed during treatment and for 4 months after the final dose. Pediatric Use In KEYNOTE-051, 161 pediatric patients (62 pediatric patients ...
Phase 2 “KidCOVE” study of mRNA-1273 in young children:The Phase 2 study of mRNA-1273 in pediatric population ages 6 months to 11 years will start in the near-term. Phase 1/2 study of mRNA-1273 in Japan: The Phase 1/2 study of Moderna’s vacci...
The agency determined that the known and potential benefits of the Moderna and Pfizer-BioNTech COVID-19 vaccines outweigh the known and potential risks in the pediatric populations authorized for use for each vaccine. The Moderna vaccine is administered as a primary series of two doses, one month...
Because of the potential for serious adverse reactions in breastfed children, advise women not to breastfeed during treatment and for 4 months after the last dose. Pediatric Use In KEYNOTE-051, 173 pediatric patient...